Published online before print August 25, 2003, doi: 10.1161/01.CIR.0000087593.07533.9B
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:1191.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs
From the Divisions of Preventive Medicine (T.K., R.J.G., J.E.B., J.M.G.), Aging (T.K., J.M.G.), and Cardiovascular Disease (J.M.G.), Department of Medicine, Brigham and Women’s Hospital, and Department of Ambulatory Care and Prevention (J.E.B.), Harvard Medical School; the Departments of Epidemiology (T.K., A.M.W., J.E.B., K.A.C.) and Biostatistics (R.J.G.), Harvard School of Public Health; the Massachusetts Veterans Epidemiology Research and Information Center (J.M.G.), Boston VA Healthcare System, Boston, Mass; the Epidemiology Division (A.M.W.), Ingenix Pharmaceutical Services, Auburndale, Mass; the Departments of Medicine and Epidemiology and Public Health (C.H.H.), University of Miami School of Medicine, Miami, Fla; and Mount Sinai Medical Center–Miami Heart Institute, Miami Beach, Fla.
Correspondence to Tobias Kurth, MD, ScD, Brigham and Women’s Hospital, Division of Preventive Medicine, 900 Commonwealth Ave E, Boston, MA 02215-1204. E-mail tkurth{at}rics.bwh.harvard.edu
Received March 24, 2003; revision received May 15, 2003; accepted May 16, 2003.
Background— There is clear evidence from numerous randomized trials and their meta-analyses that aspirin reduces risks of first myocardial infarction (MI). Recent data also suggest that other nonsteroidal anti-inflammatory drugs (NSAIDs) may interfere with this benefit of aspirin.
Methods and Results— We performed subgroup analysis from a 5-year randomized, double-blind, placebo-controlled trial of 325 mg aspirin on alternate days among 22 071 apparently healthy US male physicians with prospective observational data on use of NSAIDs. A total of 378 MIs were confirmed, 139 in the aspirin group and 239 in the placebo group. Aspirin conferred a statistical extreme (P<0.00001) 44% reduction in risk of first MI. Among participants randomized to aspirin, use of NSAIDs on 1 to 59 d/y was not associated with MI (multivariable adjusted relative risk [RR], 1.21; 95% confidence interval [CI], 0.78 to 1.87), whereas the use of NSAIDs on 
60 d/y was associated with MI (RR, 2.86; 95% CI, 1.25 to 6.56) compared with no use of NSAIDs. In the placebo group, the RRs for MI across the same categories of NSAID use were 1.14 (95% CI, 0.81 to 1.60) and 0.21 (95% CI, 0.03 to 1.48).
Conclusions— These data suggest that regular but not intermittent use of NSAIDs inhibits the clinical benefits of aspirin. Chance, bias, and confounding remain plausible alternative explanations, despite the prospective design and adjustment for covariates. Nonetheless, we believe the most plausible interpretation of the data to be that regular but not intermittent use of NSAIDs inhibits the clinical benefit of aspirin on first MI.
Key Words: myocardial infarction • aspirin • prevention • epidemiology
This article has been cited by other articles:
 |
|
 |
|
  C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Gengo, L. Rubin, M. Robson, M. Rainka, M. F. Gengo, D. E. Mager, and V. Bates Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis J. Clin. Pharmacol., January 1, 2008; 48(1): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Hunt, D. Choquette, B. N. Craig, C. De Angelis, F. Habal, G. Fulthorpe, J. I. Stewart, A. G.G. Turpie, and P. Davis Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs? Can Fam Physician, July 1, 2007; 53(7): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 M E Farkouh, J D Greenberg, R V Jeger, K Ramanathan, F W A Verheugt, J H Chesebro, H Kirshner, J S Hochman, C L Lay, S Ruland, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Ann Rheum Dis, June 1, 2007; 66(6): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.K.S. Ong, P. Lirk, C.H. Tan, and R.A. Seymour An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs Clin. Med. Res., March 1, 2007; 5(1): 19 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. White Cardiovascular Effects of the Cyclooxygenase Inhibitors Hypertension, March 1, 2007; 49(3): 408 - 418. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rahme, M. Bardou, K. Dasgupta, Y. Toubouti, J. Ghosn, and A. N. Barkun Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study Rheumatology, February 1, 2007; 46(2): 265 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Bassand Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G35 - G37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurth Letter by Kurth Regarding Article, "Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events" Circulation, September 12, 2006; 114(11): e495 - e495. [Full Text] [PDF]
|
|
|
|
|
|
A. T. Chan, G. C. Curhan, E. B. Rimm, W. C. Willett, C. S. Fuchs, J. E. Manson, C. M. Albert, C. U. Chae, and K. M. Rexrode Response to Letter Regarding Article, "Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events" Circulation, September 12, 2006; 114(11): e496 - e496. [Full Text] [PDF]
|
|
|
|
|
|
A. T. Chan, J. E. Manson, C. M. Albert, C. U. Chae, K. M. Rexrode, G. C. Curhan, E. B. Rimm, W. C. Willett, and C. S. Fuchs Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events Circulation, March 28, 2006; 113(12): 1578 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Raghavan, D. W Laight, K. M Shaw, and M. H Cummings Review: Aspirin and diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2): 74 - 82. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Sirvinskas, A. Veikutiene, P. Grybauskas, J. Cimbolaityte, A. Mongirdiene, V. Veikutis, and L. Raliene Influence of aspirin or heparin on platelet function and postoperative blood loss after coronary artery bypass surgery Perfusion, January 1, 2006; 21(1): 61 - 66. [Abstract] [PDF]
|
|
|
|
 |
|
 P. J. Mason, A. K. Jacobs, and J. E. Freedman Aspirin Resistance and Atherothrombotic Disease J. Am. Coll. Cardiol., September 20, 2005; 46(6): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L Corman, B. A Fedutes, and N. T Ansani Impact of Nonsteroidal Antiinflammatory Drugs on the Cardioprotective Effects of Aspirin Ann. Pharmacother., June 1, 2005; 39(6): 1073 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Bates and W. C. Lau Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease Circulation, May 3, 2005; 111(17): e267 - e271. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sturmer, S. Schneeweiss, M. A. Brookhart, K. J. Rothman, J. Avorn, and R. J. Glynn Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly Am. J. Epidemiol., May 1, 2005; 161(9): 891 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Capone, M. G. Sciulli, S. Tacconelli, M. Grana, E. Ricciotti, G. Renda, P. Di Gregorio, G. Merciaro, and P. Patrignani Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1295 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker, N. R. Cook, I-M. Lee, D. Gordon, J. M. Gaziano, J. E. Manson, C. H. Hennekens, and J. E. Buring A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women N. Engl. J. Med., March 31, 2005; 352(13): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanderson, J. Emery, T. Baglin, and A.-L. Kinmonth Narrative Review: Aspirin Resistance and Its Clinical Implications Ann Intern Med, March 1, 2005; 142(5): 370 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Schulman Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, October 20, 2004; 292(15): 1875 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van Ryn, M. Kink-Eiband, I. Kuritsch, U. Feifel, G. Hanft, G. Wallenstein, G. Trummlitz, and M. Pairet Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers J. Clin. Pharmacol., July 1, 2004; 44(7): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Garcia Rodriguez, C. Varas-Lorenzo, A. Maguire, and A. Gonzalez-Perez Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population Circulation, June 22, 2004; 109(24): 3000 - 3006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Curtis and H. M. Krumholz The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: Is it time to believe the hype? J. Am. Coll. Cardiol., March 17, 2004; 43(6): 991 - 993. [Full Text] [PDF]
|
|
|
|
|
|
J.-E. Gottenberg, C. Sordet, J. Sibilia, T. Kurth, R. J. Glynn, A. M. Walker, K. A. Chan, J. E. Buring, C. H. Hennekens, and J. M. Gaziano Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs * Response Circulation, March 9, 2004; 109 (9): e157 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J Hankey and J. W Eikelboom Aspirin resistance BMJ, February 28, 2004; 328(7438): 477 - 479. [Full Text] [PDF]
|
|
|
|
|
|
M. T. Eliasziw, M. D. Hill, T. Kurth, R. J. Glynn, A. M. Walker, K. A. Chan, J. E. Buring, C. H. Hennekens, and J. M. Gaziano Throw Away the Aspirin and Take Nonsteroidal Anti-Inflammatory Drugs for the Primary Prevention of Myocardial Infarction * Response Circulation, February 24, 2004; 109 (7): e65 - e66. [Full Text] [PDF]
|
|
|
|
|
|
W. H. Frishman Cyclooxygenase inhibition in patients with coronary artery disease J. Am. Coll. Cardiol., February 18, 2004; 43(4): 532 - 533. [Full Text] [PDF]
|
|
|
|
|
|
W. C. Lau, P. A. Gurbel, P. B. Watkins, C. J. Neer, A. S. Hopp, D. G.M. Carville, K. E. Guyer, A. R. Tait, and E. R. Bates Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance Circulation, January 20, 2004; 109(2): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E Kimmel and B. L Strom Giving aspirin and ibuprofen after myocardial infarction BMJ, December 6, 2003; 327(7427): 1298 - 1299. [Full Text] [PDF]
|
|
|
|
 |
|
 Do Other NSAIDs Negate the Clinical Benefit of Aspirin? Journal Watch Cardiology, November 21, 2003; 2003(1121): 5 - 5. [Full Text]
|
|
|
|
|
|
Minerva BMJ, September 27, 2003; 327(7417): 758 - 758. [Full Text] [PDF]
|
|